Molecular oncology
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén
Published: 202610.1002/1878-0261.70203
Abstract
PI3K inhibitors (PI3Ki) have shown promise in some hematological cancers, but further development has been hampered by reports of serious immune-related adverse effects. Thus, identification of effective PI3Ki lacking these adverse effects is desirab…
Preview only. Read the full abstract at the source